Overview

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
Phase:
Phase 2
Details
Lead Sponsor:
Pliant Therapeutics, Inc.
Collaborator:
Stanford University